The administration of many cancer drugs is tailored to genetic tests. Some genomic events,
eg, alterations of EGFR or BRAF oncogenes, result in the conformational change of the …

Targeting actionable fusions has emerged as a promising approach to cancer treatment.
Next-generation sequencing (NGS)–based techniques have unveiled the landscape of …

Neurotrophic tyrosine kinase (NTRK) fusions involving NTRK1, NTRK2, and NTRK3 were
found in a broad range of solid tumors as driver gene variants. However, the prevalence of …

Introduction To date, several emerging biomarkers have gained considerable interest in the
field of predictive molecular oncology. The advent of precision medicine has led to the …

A number of innovative drugs, developed for precision medicine, have shown impressive
activity in neoplastic patients with rare molecular targets, independently from the site and …

Tissue-agnostic drug development is a major step forward in offering treatment options for
rare tumors. Sarcomas are heterogeneous rare malignancies with more than 100 subtypes …

The concept of neurotrophic factor tyrosine kinase receptor (NTRK) fusion tumor has
emerged in recent years. Moreover, NTRK fusion is unusual in common tumors but can often …

Abstract NTRK1/2/3 rearrangements have been identified as oncogenic drivers in a variety
of tumors including those in the uterine cervix, and rarely, the uterine corpus. We report 2 …

Large-scale tumor molecular profiling has revealed that diverse cancer histologies are
driven by common pathways with unifying biomarkers that can be exploited therapeutically …

Cardiac tumors are rare and encompass a variety of presentations. Clinica symptoms are
usually nonspecific, but they can present as obstructive, embolic, or constitutional symptoms …